In neurofibromatosis type 2, which screening test should be performed annually to monitor brain involvement?

Prepare for the NBME Form 9 Test with our engaging quiz. Utilize multiple choice questions and explanations. Excel in your exam with thorough study tools and resources!

Multiple Choice

In neurofibromatosis type 2, which screening test should be performed annually to monitor brain involvement?

Explanation:
In neurofibromatosis type 2, the main concern is the development and progression of intracranial tumors, especially vestibular schwannomas and other CNS tumors. Magnetic resonance imaging of the brain with contrast provides the clearest, most sensitive view of soft tissue in the brain and posterior fossa, allowing detection of small tumors and accurate assessment of their size and location. Because tumors can develop or grow over time, an annual MRI brain is the most effective way to monitor brain involvement and guide management without exposing the patient to ionizing radiation. An eye exam can reveal ocular findings seen in NF2 but does not assess brain tumors; EEG measures brain electrical activity rather than anatomy; and a CT scan of the chest is not relevant to monitoring CNS involvement.

In neurofibromatosis type 2, the main concern is the development and progression of intracranial tumors, especially vestibular schwannomas and other CNS tumors. Magnetic resonance imaging of the brain with contrast provides the clearest, most sensitive view of soft tissue in the brain and posterior fossa, allowing detection of small tumors and accurate assessment of their size and location. Because tumors can develop or grow over time, an annual MRI brain is the most effective way to monitor brain involvement and guide management without exposing the patient to ionizing radiation. An eye exam can reveal ocular findings seen in NF2 but does not assess brain tumors; EEG measures brain electrical activity rather than anatomy; and a CT scan of the chest is not relevant to monitoring CNS involvement.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy